Inter- and intraspecies polymorphisms in the cholecystokinin-B/gastrin receptor alter drug efficacy.
The brain cholecystokinin-B/gastrin receptor (CCK-BR) is a major target for drug development because of its postulated role in modulating anxiety, memory, and the perception of pain. Drug discovery efforts have resulted in the identification of small synthetic molecules that can selectively activate this receptor subtype. These drugs include the peptide-derived compound PD135,158 as well as the nonpeptide benzodiazepine-based ligand, L-740,093 (S enantiomer). We now report that the maximal level of receptor-mediated second messenger signaling that can be achieved by these compounds (drug efficacy) markedly differs among species homologs of the CCK-BR. Further analysis reveals that the observed differences in drug efficacy are in large part explained by single or double aliphatic amino acid substitutions between respective species homologs. This interspecies variability in ligand efficacy introduces the possibility of species differences in receptor-mediated function, an important consideration when selecting animal models for preclinical drug testing. The finding that even single amino acid substitutions can significantly affect drug efficacy prompted us to examine ligand-induced signaling by a known naturally occurring human CCK-BR variant (glutamic acid replaced by lysine in position 288; 288E --> K). When examined using the 288E --> K receptor, the efficacies of both PD135,158 and L-740, 093 (S) were markedly increased compared with values obtained with the wild-type human protein. These observations suggest that functional variability resulting from human receptor polymorphisms may contribute to interindividual differences in drug effects.
Kopin
A S
AS
Division of Gastroenterology and GRASP Digestive Disease Center, Tupper Research Institute, New England Medical Center, Tufts University School of Medicine, Boston, MA 02111, USA.
McBride
E W
EW
Gordon
M C
MC
Quinn
S M
SM
Beinborn
M
M
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D019556:COS Cells; D004285:Dogs; D004789:Enzyme Activation; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008536:Meglumine / Q000031:analogs & derivatives* / Q000494:pharmacology; D051379:Mice; D010671:Phenylurea Compounds / Q000494:pharmacology*; D011110:Polymorphism, Genetic; D011869:Radioligand Assay; D011949:Receptors, Cholecystokinin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics*; D011994:Recombinant Proteins / Q000235:genetics; D013045:Species Specificity; D010738:Type C Phospholipases / Q000378:metabolism
D001570:Benzodiazepinones; D007211:Indoles; D010671:Phenylurea Compounds; D011949:Receptors, Cholecystokinin; D011994:Recombinant Proteins; C065600:PD 135158; C090649:L 740093; D008536:Meglumine; D010738:Type C Phospholipases